The first malaria vaccine candidate (RTS,S/AS01) to reach Phase 3 trials is partially effective against clinical disease in young African children up to four years after vaccination, according to final trial data published in The Lancet, which will now be evaluated by the European Medicines Agency (EMA).
Certara®, a global biosimulation technology-enabled drug development consultancy, and CISCRP, an independent nonprofit organization dedicated to educating and informing the public and patients about clinical research, announced that they are partnering to produce high-quality lay summaries of clinical trials.
Catalent, a global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, announced that it has received a project grant as part of a consortium.
TrialScope, a clinical trial transparency and compliance solutions provider, announced the availability of Convert, a free online clinical trial data conversion service.
PAREXEL introduced the latest version of its Regulatory Information Management (RIM) platform: LIQUENT InSight® 6.0